India-based biopharmaceutical company Suven Life Sciences has got its first product patent from the US Patent office
Suven Life Sciences has got its first product patent from the US Patent office. The patent granted includes the class of selective Serotonin receptor affinity compounds and are being developed as therapeutic agents. These compounds are useful in the treatment of neuro-degenarative disorders like Alzheimer’s disease, Parkinson disease, Schizophrenia disease and Huntington’s disease.
Suven had submitted its first Investigational New Drug (IND) application to conduct phase 1 clinical trial for their developmental candidate SUVN-502 obesity, along with developmental candidates in Alzheimer’s disease and Schizophrenia.